8-K Announcements
6Material company update
Apr 14, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Apr 10, 2026·SEC
Microbot Medical Inc.(MBOT)Earnings, Financials & Key Ratios
MBOT•NASDAQ
$2.19
$147M mkt cap·Price updated May 6, 2026
AboutMicrobot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.Show more
- Revenue$0
- EBITDA-$12M-18.3%
- Net Income-$11M-6.5%
- EPS (Diluted)-0.73+30.5%
- ROE-284.97%-56.4%
- ROIC-624.78%-216.8%
- Debt/Equity0.03-38.7%
MBOT Key Insights
Microbot Medical Inc. (MBOT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 53.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MBOT Price & Volume
Microbot Medical Inc. (MBOT) stock price & volume — 10-year historical chart
Loading chart...
MBOT Growth Metrics
Microbot Medical Inc. (MBOT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.47%
Return on Capital
10 Years-116.17%
5 Years-131.81%
3 Years-190.04%
Last Year-286.61%
MBOT Recent Earnings
Microbot Medical Inc. (MBOT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
Mar 26, 2026EPS
$0.04
Est $0.06
+33.3%
Revenue
—
Est $113,333
Q4 2025
Nov 12, 2025EPS
$0.07
Est $0.06
-16.7%
Revenue
—
Est $600,000
Q3 2025
Aug 12, 2025EPS
$0.10
Est $0.08
-25.0%
Revenue
—
Est $630,000
Q2 2025
May 14, 2025EPS
$0.08
Est $0.13
+38.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.04vs $0.06+33.3% | —vs $113,333 |
| Q4 2025 | Nov 12, 2025 | $0.07vs $0.06-16.7% | —vs $600,000 |
| Q3 2025 | Aug 12, 2025 | $0.10vs $0.08-25.0% | —vs $630,000 |
| Q2 2025 | May 14, 2025 | $0.08vs $0.13+38.5% | — |
Based on last 12 quarters of dataView full earnings history →
MBOT Peer Comparison
Microbot Medical Inc. (MBOT) competitors in Robotic and computer-assisted surgery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SSYS | 790.28M | 9.25 | -5.44 | -8.79% | -22.69% | -15.29% | 0.04 | |
 RBOT | 2.72M | 0.42 | -0.05 | -333.19% | 0.79 | |||
 TRVI | 2.02B | 14.26 | -49.17 | -24.53% | 0.00 | |||
 ISRG | 160.44B | 451.73 | 57.40 | 20.51% | 28.15% | 16.89% | 0.02 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 SYK | 111.96B | 292.33 | 34.80 | 11.16% | 12.92% | 15.04% | 0.66 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 |
Compare MBOT vs Peers
Microbot Medical Inc. (MBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MBOT Income Statement
Microbot Medical Inc. (MBOT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 10K | 21K | 54K | 84K | 0 | 0 | 0 | 106K | 91K | 48K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -10K▲ 0% | -21K▼ 110.0% | -54K▼ 157.1% | -84K▼ 55.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -106K▲ 0% | -91K▲ 14.2% | -48K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -108.55% | -110% | -157.14% | -55.56% | 100% | - | - | - | 14.15% | - |
| Operating Expenses | 9.63M | 5.27M | 7.24M | 7.16M | 9.09M | 11.36M | 13.28M | 9.75M | 11.53M | 13.99M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 8.77M | 4.2M | 4.73M | 4.18M | 5.89M | 5.41M | 5.58M | 4.13M | 5M | 7.31M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.11M | 1.28M | 2.86M | 2.97M | 3.4M | 6.15M | 7.74M | 5.72M | 6.63M | 6.68M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -249K | -213K | -476K | 0 | -195K | -206K | -36K | -106K | -91K | 0 |
| Operating Income | -9.63M▲ 0% | -5.27M▲ 45.3% | -7.24M▼ 37.5% | -7.24M▲ 0.1% | -9.09M▼ 25.5% | -11.36M▼ 25.0% | -13.28M▼ 16.9% | -9.86M▲ 25.8% | -11.63M▼ 18.0% | -14.04M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 73.76% | 45.33% | -37.54% | 0.06% | -25.54% | -24.95% | -16.94% | 25.8% | -17.96% | - |
| EBITDA | -9.63M | -5.25M | -7.19M | -7.16M | -9.02M | -11.28M | -13.18M | -9.75M | -11.53M | -13.97M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 72.96% | 45.5% | -37.06% | 0.47% | -26.06% | -25.05% | -16.82% | 26.03% | -18.31% | -37.48% |
| D&A (Non-Cash Add-back) | 10K | 21K | 54K | 84K | 68K | 76K | 102K | 106K | 91K | 63K |
| EBIT | -9.63M | -5.27M | -7.22M | -7.14M | -9.09M | -11.36M | -13.44M | -10.74M | -11.44M | -13.49M |
| Net Interest Income | 0 | 0 | 0 | -103K | -79.92K | 44K | 54K | 228K | 182K | 365K |
| Interest Income | 0 | 0 | 0 | 0 | 80 | 44K | 54K | 228K | 182K | 365K |
| Interest Expense | 334K | 238K | 0 | 103K | 80K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -28K | -2.32M | -16K | -7K | -80K | 44K | 113K | -885K | 182K | 965K |
| Pretax Income | -9.66M▲ 0% | -7.59M▲ 21.5% | -7.26M▲ 4.3% | -7.25M▲ 0.2% | -9.17M▼ 26.5% | -11.31M▼ 23.4% | -13.17M▼ 16.4% | -10.74M▲ 18.4% | -11.44M▼ 6.5% | -13.07M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.28% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -9.66M▲ 0% | -7.59M▲ 21.5% | -7.26M▲ 4.3% | -7.25M▲ 0.2% | -9.17M▼ 26.5% | -11.31M▼ 23.4% | -13.17M▼ 16.4% | -10.74M▲ 18.4% | -11.44M▼ 6.5% | -13.07M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 73.46% | 21.46% | 4.34% | 0.18% | -26.52% | -23.38% | -16.4% | 18.44% | -6.55% | -16.64% |
| Net Income (Continuing) | -9.66M | -7.59M | -7.26M | -7.25M | -9.17M | -11.31M | -13.17M | -10.74M | -11.44M | -13.07M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.14▲ 0% | -0.85▲ 91.6% | -0.81▲ 4.7% | -1.70▼ 109.9% | -1.29▲ 24.1% | -1.59▼ 23.3% | -1.81▼ 13.8% | -1.05▲ 42.0% | -0.73▲ 30.5% | -0.27▲ 0% |
| EPS Growth % | -40.83% | 91.62% | 4.71% | -109.88% | 24.12% | -23.26% | -13.84% | 41.99% | 30.48% | 54.47% |
| EPS (Basic) | -10.14 | -0.85 | -0.81 | -1.70 | -1.29 | -1.59 | -1.81 | -1.05 | -0.73 | - |
| Diluted Shares Outstanding | 952.89K | 8.92M | 8.92M | 4.27M | 7.12M | 7.11M | 7.26M | 10.2M | 15.64M | 48.1M |
| Basic Shares Outstanding | 952.89K | 8.92M | 8.92M | 4.27M | 7.12M | 7.11M | 7.26M | 10.2M | 15.64M | 48.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MBOT Balance Sheet
Microbot Medical Inc. (MBOT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.31M | 10.93M | 5.83M | 35.94M | 25.25M | 15.88M | 8.81M | 7.92M | 5.82M | 80.78M |
| Cash & Short-Term Investments | 2.71M | 10.79M | 5.24M | 31.29M | 24.65M | 15.49M | 8.28M | 6.38M | 5.47M | 80.16M |
| Cash Only | 2.71M | 10.79M | 5.24M | 28.77M | 19.65M | 13.49M | 2.52M | 2.47M | 3.11M | 6.7M |
| Short-Term Investments | 0 | 0 | 0 | 2.52M | 5M | 2M | 5.76M | 3.92M | 2.36M | 73.45M |
| Accounts Receivable | 15K | 35K | 65K | 101K | 0 | 174K | 103K | 1.49M | 300K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 400K | 27K | 437K | 4.36M | 424K | 87K | 3K | 49K | 49K | 627K |
| Total Non-Current Assets | 53K | 90K | 259K | 1.19M | 1.03M | 888K | 723K | 406K | 212K | 975K |
| Property, Plant & Equipment | 53K | 90K | 259K | 1.19M | 1.03M | 888K | 723K | 406K | 212K | 975K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 3.37M▲ 0% | 11.02M▲ 227.2% | 6.09M▼ 44.7% | 37.13M▲ 509.6% | 26.28M▼ 29.2% | 16.77M▼ 36.2% | 9.54M▼ 43.1% | 8.33M▼ 12.7% | 6.03M▼ 27.6% | 81.76M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -84.13% | 227.2% | -44.74% | 509.62% | -29.22% | -36.2% | -43.12% | -12.69% | -27.57% | 2107.32% |
| Total Current Liabilities | 783K | 528K | 4.76M | 4.83M | 1.34M | 1.98M | 2.07M | 3.79M | 2.46M | 2.93M |
| Accounts Payable | 512K | 78K | 630K | 284K | 275K | 279K | 116K | 357K | 165K | 509K |
| Days Payables Outstanding | 18.69K | 1.36K | 4.26K | 1.23K | - | - | - | 1.23K | 661.81 | 2.59K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 283K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 386K | 3.38M | 3.73M | 0 | 0 | 298K | 804K | 1.41M | 0 |
| Current Ratio | 4.23x | 20.70x | 1.23x | 7.45x | 18.78x | 8.00x | 4.26x | 2.09x | 2.37x | 2.37x |
| Quick Ratio | 4.23x | 20.70x | 1.23x | 7.45x | 18.78x | 8.00x | 4.26x | 2.09x | 2.37x | 2.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 889K | 528K | 0 | 760K | 626K | 402K | 179K | 40K | 41K | 602K |
| Long-Term Debt | 76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 760K | 626K | 402K | 179K | 40K | 41K | 738K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 813K | 528K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.67M | 1.06M | 4.76M | 5.59M | 1.97M | 2.39M | 2.25M | 3.83M | 2.5M | 3.54M |
| Total Debt | 76K | 0 | 0 | 903K | 813K | 680K | 462K | 231K | 111K | 899K |
| Net Debt | -2.63M | -10.79M | -5.24M | -27.87M | -18.84M | -12.81M | -2.06M | -2.24M | -3M | -5.8M |
| Debt / Equity | 0.04x | - | - | 0.03x | 0.03x | 0.05x | 0.06x | 0.05x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.42x |
| Interest Coverage | -28.85x | -22.13x | - | -70.29x | -113.61x | - | - | - | - | - |
| Total Equity | 1.7M▲ 0% | 9.96M▲ 487.5% | 1.33M▼ 86.7% | 31.54M▲ 2271.4% | 24.31M▼ 22.9% | 14.38M▼ 40.8% | 7.29M▼ 49.3% | 4.5M▼ 38.2% | 3.53M▼ 21.6% | 78.22M▲ 0% |
| Equity Growth % | 607.78% | 487.5% | -86.65% | 2271.43% | -22.93% | -40.84% | -49.32% | -38.25% | -21.57% | 2703.43% |
| Book Value per Share | 1.78 | 1.12 | 0.15 | 7.39 | 3.42 | 2.02 | 1.00 | 0.44 | 0.23 | 1.63 |
| Total Shareholders' Equity | 1.7M | 9.96M | 1.33M | 31.54M | 24.31M | 14.38M | 7.29M | 4.5M | 3.53M | 78.22M |
| Common Stock | 266K | 27K | 31K | 72K | 72K | 72K | 80K | 118K | 195K | 659K |
| Retained Earnings | -13.04M | -20.62M | -27.86M | -35.11M | -44.28M | -55.59M | -68.76M | -79.5M | -90.94M | -100.62M |
| Treasury Stock | 0 | 0 | -3.38M | -3.38M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MBOT Cash Flow Statement
Microbot Medical Inc. (MBOT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -786K | -4.86M | -5.31M | -6.45M | -7.25M | -9.35M | -11.55M | -8.53M | -8.83M | -8.83M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -2.75% | -517.81% | -9.35% | -21.49% | -12.42% | -28.99% | -23.47% | 26.11% | -3.45% | -82.32% |
| Net Income | -9.66M | -7.59M | -7.26M | -7.25M | -9.17M | -11.31M | -13.17M | -10.74M | -11.44M | -13.07M |
| Depreciation & Amortization | 10K | 21K | 54K | 84K | 68K | 76K | 102K | 106K | 91K | 63K |
| Stock-Based Compensation | 676K | 479K | 1.4M | 1.1M | 1.94M | 1.39M | 1.75M | 1.39M | 1.35M | 1.1M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7.33M | 2.32M | 74K | -121K | -70K | 0 | -7K | 718K | 234K | -281K |
| Working Capital Changes | 862K | -83K | 423K | -266K | -18K | 497K | -228K | -11K | 942K | 1.21M |
| Change in Receivables | 538K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | -140K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -25K | -58K | -223K | -2.45M | -2.77M | 3.2M | -3.84M | 1.97M | 1.54M | -69.36M |
| Capital Expenditures | -25K | -58K | -223K | -216K | -91K | -69K | -84K | -33K | -25K | -42K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 259K | -200K | 0 | -3K | 3K | 0 | 0 |
| Cash from Financing | 3.08M | 13.02M | -18K | 36.77M | -3.38M | 0 | 4.32M | 6.56M | 7.94M | 86.57M |
| Debt Issued (Net) | 750K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 12.7M | 0 | 36.77M | -3.38M | 0 | 4.32M | 6.56M | 7.94M | 86.57M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.33M | 317K | -18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.27M▲ 0% | 8.11M▲ 256.7% | -5.55M▼ 168.5% | 27.87M▲ 602.0% | -13.39M▼ 148.1% | -6.15M▲ 54.1% | -11.06M▼ 79.7% | -2K▲ 100.0% | 646K▲ 32400.0% | 6.23M▲ 0% |
| Free Cash Flow | -811K▲ 0% | -4.91M▼ 505.9% | -5.53M▼ 12.6% | -6.67M▼ 20.5% | -7.34M▼ 10.1% | -9.42M▼ 28.3% | -11.63M▼ 23.5% | -8.57M▲ 26.4% | -8.85M▼ 3.3% | -11.02M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -5.74% | -505.92% | -12.6% | -20.5% | -10.14% | -28.33% | -23.45% | 26.36% | -3.34% | -22.87% |
| FCF per Share | -0.85 | -0.55 | -0.62 | -1.56 | -1.03 | -1.33 | -1.60 | -0.84 | -0.57 | -0.57 |
| FCF Conversion (FCF/Net Income) | 0.08x | 0.64x | 0.73x | 0.89x | 0.79x | 0.83x | 0.88x | 0.79x | 0.77x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MBOT Key Ratios
Microbot Medical Inc. (MBOT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1418.94% | -130.17% | -128.56% | -44.09% | -32.84% | -58.48% | -121.53% | -182.19% | -284.97% | -37.06% |
| Return on Invested Capital (ROIC) | - | - | - | - | -149.11% | -242.02% | -292.96% | -197.21% | -624.78% | -624.78% |
| Debt / Equity | 0.04x | - | - | 0.03x | 0.03x | 0.05x | 0.06x | 0.05x | 0.03x | 0.03x |
| Interest Coverage | -28.85x | -22.13x | - | -70.29x | -113.61x | - | - | - | - | - |
| FCF Conversion | 0.08x | 0.64x | 0.73x | 0.89x | 0.79x | 0.83x | 0.88x | 0.79x | 0.77x | 0.84x |
| Revenue Growth | -100% | - | - | - | - | - | - | - | - | - |
MBOT SEC Filings & Documents
Microbot Medical Inc. (MBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)
MBOT Frequently Asked Questions
Microbot Medical Inc. (MBOT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Microbot Medical Inc. (MBOT) grew revenue by 0.0% over the past year. Growth has been modest.
Microbot Medical Inc. (MBOT) reported a net loss of $13.1M for fiscal year 2024.
Dividend & Returns
Microbot Medical Inc. (MBOT) has a return on equity (ROE) of -285.0%. Negative ROE indicates the company is unprofitable.
Microbot Medical Inc. (MBOT) had negative free cash flow of $11.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More MBOT
Microbot Medical Inc. (MBOT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates